Benzinga | Jul 8, 2021 01:26PM EDT

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu

* Daiichi Sankyo Co Ltd (OTC:DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma.

* The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.

* The primary endpoint of the trial is overall survival.

* Secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity.

* The study will enroll approximately 490 patients.

* Price Action: AZN shares are down 1.15% at $59.08 during the market session on the last check Thursday.